UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Effect of Interleukin-10 on Meningeal Inflammation in Experimental Bacterial Meningitis

The Journal of infectious diseases, 1997-11, Vol.176 (5), p.1239-1246

1997

Volltextzugriff (PDF)

Systemic cytokine response in children bitten by snakes in Costa Rica

Pediatric emergency care, 2001-12, Vol.17 (6), p.425-429

2001

Volltextzugriff (PDF)

Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome

The New England journal of medicine, 2019-11, Vol.381 (20), p.1918-1928

2019

Volltextzugriff (PDF)

Albendazole therapy for Microsporidium diarrhea in immunocompetent Costa Rican children

The Pediatric infectious disease journal, 2004-10, Vol.23 (10), p.915-918

2004

Volltextzugriff (PDF)

Fusarium proliferatum from rainwater and rooted garlic show genetic and pathogenicity differences

European journal of plant pathology, 2016-09, Vol.146 (1), p.199-206

2016

Volltextzugriff (PDF)

Transgenic Arabidopsis thaliana expressing a barley UDP-glucosyltransferase exhibit resistance to the mycotoxin deoxynivalenol

Journal of experimental botany, 2012-08, Vol.63 (13), p.4731-4740

2012

Volltextzugriff (PDF)

Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study

Modern rheumatology, 2022-02, Vol.32 (2), p.413-421

2022

Volltextzugriff (PDF)

Kaurenic acid: Evaluation of the in vivo and in vitro antitumor activity on murine melanoma

Indian journal of pharmacology, 2011-11, Vol.43 (6), p.683-688

2011

Volltextzugriff (PDF)

Incidence rates of suicidal behaviors and treated depression in patients with and without psoriatic arthritis using the Clinical Practice Research Datalink

Modern rheumatology, 2016-09, Vol.26 (5), p.774-779

2016

Volltextzugriff (PDF)

Toys in a pediatric hospital: Are they a bacterial source?

American journal of infection control, 2004-08, Vol.32 (5), p.287-290

2004

Volltextzugriff (PDF)

Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials

ACR open rheumatology, 2020-08, Vol.2 (8), p.459-470

2020

Volltextzugriff (PDF)

Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink

Drug safety, 2022-11, Vol.45 (11), p.1403-1411

2022

Volltextzugriff (PDF)

Educational Inequalities and Cardiovascular Risk Factors. A Cross-Sectional Population-Based Study in Southern Spain

Public health Nursing, 2013-05, Vol.30 (3), p.202-212

2013

Volltextzugriff (PDF)

40666 Long-term Safety of Apremilast From a Pooled Analysis of 15 Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Oral Ulcers Associated With Behçet’s Syndrome

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB190-AB190

2023

Volltextzugriff (PDF)

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial

Rheumatology (Oxford, England), 2018-07, Vol.57 (7), p.1253-1263

2018

Volltextzugriff (PDF)

Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial

Journal of the American Academy of Dermatology, 2022-01, Vol.86 (1), p.77-85

2022

Volltextzugriff (PDF)

Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study

Journal of the American Academy of Dermatology, 2020-07, Vol.83 (1), p.96-103

2020

Volltextzugriff (PDF)

Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial

Journal of the American Academy of Dermatology, 2024-06, Vol.90 (6), p.1232-1239

2024

Volltextzugriff (PDF)

42163 Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB122-AB122

2023

Volltextzugriff (PDF)

Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4

Regulatory toxicology and pharmacology, 2021-10, Vol.125, p.104985, Article 104985

2021

Volltextzugriff (PDF)

Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial

Journal of the European Academy of Dermatology and Venereology, 2023-02, Vol.37 (2), p.348-355

2023

Volltextzugriff (PDF)

Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study

Journal of the American Academy of Dermatology, 2020-02, Vol.82 (2), p.389-397

2020

Volltextzugriff (PDF)

16349 Rates of herpes zoster, hepatitis C, and tuberculosis among patients with psoriasis treated with apremilast, biologics, disease-modifying antirheumatic drugs, and corticosteroids: A cohort study in the US MarketScan database

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB61-AB61

2020

Volltextzugriff (PDF)

Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial

Journal of the American Academy of Dermatology, 2023-02, Vol.88 (2), p.430-433

2023

Volltextzugriff (PDF)

Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome

American journal of clinical dermatology, 2023-09, Vol.24 (5), p.809-820

2023

Volltextzugriff (PDF)

1 – 25 von 247

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Full Text

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(244)
Mit Volltextzugriff
(201)

Publikationsform

Artikel
(247)

Sprache

Englisch
(247)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

The Effect of Interleukin-10 on Meningeal Inflammation in Experimental Bacterial Meningitis

Systemic cytokine response in children bitten by snakes in Costa Rica

Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome

Albendazole therapy for Microsporidium diarrhea in immunocompetent Costa Rican children

Fusarium proliferatum from rainwater and rooted garlic show genetic and pathogenicity differences

Transgenic Arabidopsis thaliana expressing a barley UDP-glucosyltransferase exhibit resistance to the mycotoxin deoxynivalenol

Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study

Kaurenic acid: Evaluation of the in vivo and in vitro antitumor activity on murine melanoma

Incidence rates of suicidal behaviors and treated depression in patients with and without psoriatic arthritis using the Clinical Practice Research Datalink

Toys in a pediatric hospital: Are they a bacterial source?

Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials

Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink

Educational Inequalities and Cardiovascular Risk Factors. A Cross-Sectional Population-Based Study in Southern Spain

40666 Long-term Safety of Apremilast From a Pooled Analysis of 15 Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Oral Ulcers Associated With Behçet’s Syndrome

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial

Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial

Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study

Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial

42163 Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study

Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4

Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial

Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study

16349 Rates of herpes zoster, hepatitis C, and tuberculosis among patients with psoriasis treated with apremilast, biologics, disease-modifying antirheumatic drugs, and corticosteroids: A cohort study in the US MarketScan database

Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial

Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome

Aktive Filter

Suchergebnisse filtern